Cerapedics Inc.

Join Cerapedics at the 2026 Spine Summit Meeting!  📅 February 26 - March 1 | 🏜️Phoenix, AZ Here’s where you can find Cerapedics throughout the conference: 🔸Booth #412 Connect with us at Booth #412 — Learn more about the power of our P-15 Peptide. 🔸What's New Session: “Introducing PearlMatrix™, The First and Only Bone Growth Accelerator”  John O'Toole, M.D. | Friday, Feb. 27, 8:15-8:25am | Presentation Stage, Exhibit Hall 🔸Lunch-n-Learn: “Hungry for better outcomes? Optimizing biologics to accelerate fusion” Ken Crandall, Safdar Khan, John O'Toole, Peter Passias, Sharad Rajpal, M.D. | Friday, Feb. 27, 12:45-1:30pm | Wildflower C

Even in higher-risk patients, PearlMatrix demonstrated substantially faster fusion vs. local autograft at between 0 and 24 months.*^   And over 2x more patients fused at the 6-month mark.   To learn more, visit: www.Pearlmatrix.com.    *As demonstrated in a single-level TLIF IDE study vs. local autograft. ^High-risk includes nicotine use, BMI ≥ 30 and/or Type 2 diabetes.     #PearlMatrix #P15PeptidePower #RepairingBonesHealingLives  

Fusion takes time. ACCELERATE IT. PearlMatrix™ P-15 Peptide Enhanced Bone Graft is the first and only bone growth accelerator designed to accelerate lumbar fusion. Watch to learn how to close the surgery-to-fusion time gap. To learn more, visit https://hubs.ly/Q03VnNwW0

PearlMatrix demonstrated statistically superior fusion speed vs. local autograft between 0 and 24 months.*   And had over 2x more patients fused at 6-months. Read the study: https://lnkd.in/dKtjcve4 Now approved for all major lumbar interbody fusion procedures.   *As demonstrated in a single-level TLIF IDE study vs. local autograft.    #PearlMatrix #P15PeptidePower #RepairingBonesHealingLives     This information is intended solely for healthcare professionals.

Redefining bone repair is our commitment. At Cerapedics, we drive this with the power of P-15 Osteogenic Cell Binding Peptide and the strength of rigorous clinical evidence.    Transforming outcomes, one fusion at a time. Learn more: https://lnkd.in/e-X5j22G   #P15PeptidePower #Cerapedics #RepairingBonesHealingLives    This information is intended solely for healthcare professionals.

At Cerapedics, we’re advancing bone repair to support spine surgeons in delivering the best possible patient care.   Through ongoing education and innovation, we’re helping shape the future of spine surgery.   🔗 Explore our latest resources for clinicians and discover how we’re driving progress in bone repair: https://lnkd.in/eq5e2FGs   #P15PeptidePower #Cerapedics  #RepairingBonesHealingLives    This information is intended solely for healthcare professionals.

Join us at this week’s Seattle Science Foundation STED Talk Series for the live featured presentation, “Faster Fusion: Why It Matters and How to Achieve It,” presented by Zorica Buser, PhD, Cerapedics’ Global Head of Medical Strategy. Wednesday, February 4 7:30-8:00am PT Click here to register for Virtual Log in Details https://lnkd.in/e92jCb3D

What makes or breaks your #SpinalFusion? Not all bone grafts are the same. Most are passive. i-FACTOR® with P-15 Peptide is active - built to initiate cell attachment, the first step in the body’s bone-forming process. When #RepairingBonesHealingLives matters, unlock bone repair with the first Peptide-enhanced product. To learn more, visit https://lnkd.in/eTwrZ_dX #iFACTOR This information is intended solely for healthcare professionals.

Fusion takes time. ACCELERATE IT. PearlMatrix™ P-15 Peptide Enhanced Bone Graft is the first and only bone growth accelerator designed to accelerate lumbar fusion. Watch to learn how to close the surgery-to-fusion time gap. To learn more, visit https://hubs.ly/Q03QlSdp0

What if you could accelerate lumbar fusion for your patients?   PearlMatrix™ P-15 Peptide Enhanced Bone Graft demonstrated statistically superior fusion speed at 24 months with more than twice as many patients fused at 6 months vs. local autograft.*   To learn more, visit: https://lnkd.in/g4tHsqgH   *Demonstrated statistically superior time-to-fusion in a single-level TLIF PMA IDE study vs. local autograft.   This information is intended solely for healthcare professionals.